<DOC>
	<DOCNO>NCT02115152</DOCNO>
	<brief_summary>This randomized phase II trial compare pathologic response rate ( pCR ) early breast cancer follow neoadjuvant fluorouracil-epirubicin-cyclophosphamide ( FEC ) capecitabine-epirubicin-cyclophosphamide ( XEC ) .</brief_summary>
	<brief_title>Neoadjuvant Trial Capecitabine Axillary Lymph Node Positive Operable Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Females age 1870 histologically proven , corebiopsied , Stage IIIII invasive breast cancer No distant disease Inadequate heart liver kidney function</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Capecitabine</keyword>
	<keyword>Neoadjuvant therapy</keyword>
	<keyword>Early Breast Cancer</keyword>
</DOC>